

UNITED STATES OF AMERICA
before the
SECURITIES AND EXCHANGE COMMISSION

SECURITIES EXCHANGE ACT OF 1934
Release No. 97703 / June 12, 2023

Admin. Proc. File No. 3-19790

In the Matter of
MOLECULIN BIOTECH, INC.,
and
WALTER V. KLEMP

ORDER GRANTING REQUEST TO WITHDRAW PETITION FOR TERMINATION OF
TRADING SUSPENSION AND DISMISSING PROCEEDING

On May 1, 2020, the Commission issued an order pursuant to Section 12(k) of the Securities Exchange Act of 1934 suspending trading in the securities of Moleculin Biotech, Inc. (“Moleculin”) (CIK No. 0001659617) for the period from 9:30 a.m. EDT on May 4, 2020, through 11:59 p.m. EDT on May 15, 2020.¹ On May 7, 2020, Moleculin and Walter V. Klemp, Moleculin’s Chairman and CEO, filed a petition for termination of the trading suspension pursuant to Rule of Practice 550.² On May 11, 2020, the Commission requested additional written submissions in accordance with Rule of Practice 550(b).³ On May 29, 2020, Moleculin and Klemp withdrew their petition. On June 12, 2020, the Division of Enforcement requested that the Commission dismiss the petition and terminate the administrative proceeding.

Accordingly, it is ORDERED that Moleculin and Klemp’s request to withdraw their petition for termination of the trading suspension is granted and this proceeding is dismissed.

By the Commission.

Vanessa A. Countryman
Secretary

¹ *Moleculin Biotech, Inc.*, Exchange Act Release No. 88801, 2020 WL 2124569 (May 1, 2020).

² 17 C.F.R. § 201.550.

³ 17 C.F.R. § 201.550(b).